Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support Personalized Therapeutics Development

Generate Life Sciences (Generate) today announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, California which will enable end-to-end manufacturing for newborn stem cell biologics. This facility will represent a big step in the evolution of Generate and...

Allele Biotech to Collaborate with Cellatoz on Cell Therapy and iPSC Biobanking

Allele Biotechnology & Pharmaceuticals in San Diego, California, today announced the signing of a MOU with Cellatoz Therapeutics, a South Korean corporation, to form a business relationship on areas of mutual interest in the field of cell therapy. iPSC-based cell...

First Biobank for Chromosome 15 Disorders in Australia

The first biobank in Australia aiming to improve research and treatments into rare genetic diseases caused by changes to genes on chromosome 15, including Prader-Willi Syndrome and Angelman Syndrome, will be established at the Murdoch Children's Research Institute (MCRI). Prader-Willi...

BioLife Solutions to Acquire Biobanking Service Provider SciSafe in a $30 Million Deal

BOTHELL, Wash., Sept. 21, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it has entered into a definitive agreement to acquire SciSafe,...

Cryoport Acquires MVE Biological Solutions from Chart Industries for $320 million

Cryoport will become a leading global provider of cryogenic life sciences solutions Acquisitions of MVE, along with CRYOPDP is expected to increase Cryoport's revenue run rate to over $160 million and to be immediately accretive Blackstone to invest...

The Gift Of Life Marrow Registry To Receive Advocacy Award At World Stem Cell...

The formal ceremony of the 2020 Stem Cell and Regenerative Medicine Action Awards will take place at a gala reception and dinner on January 23, during the 15th annual World Stem Cell Summit (WSCS) at the Hyatt Regency in...

StemCyte Receives IND Clearance Of Mononuclear Stem Cells In Spinal Cord Injury Clinical Trials

On December 14, 2018, the U.S. Food and Drug Administration (FDA), approved StemCyte’s Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury. Founded in 1997,...

CRISPR Therapeutics And ViaCyte Collaborate To Create Universal Stem Cell Therapies For Diabetes

CRISPR Therapeutics and ViaCyte, Inc. have announced a collaboration focused on the discovery, development, and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes. ViaCyte is a privately-held regenerative medicine company, founded in 1999, headquartered San Diego,...

Cynata’s CYP-001 Stem Cell Therapy Meets Expectations In Phase 1 Graft-Versus-Host Disease Trial

Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company founded in 2003 that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research.. CYP-001,...

IPS HEART Aims To Use Induced Pluripotent Stem Cells To Treat Heart Attack

IPS HEART is a privately-held biopharmaceutical company, founded in 2014, dedicated to addressing heart attack, heart failure and Duchenne cardiomyopathy via next generation cellular therapy. IPS HEART was the first company to exclusively focus on induced pluripotent stem cells...

⭐ Recently Featured

🔥 Popular Posts

X